138 related articles for article (PubMed ID: 36773456)
1. 1H-Indazoles derivatives targeting PI3K/AKT/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism.
Wang S; Shi JT; Wang XR; Mu HX; Wang XT; Xu KY; Wang QS; Chen SW
Bioorg Chem; 2023 Apr; 133():106412. PubMed ID: 36773456
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
Sun X; Zhang B; Luo L; Yang Y; He B; Zhang Q; Wang L; Xu S; Zheng P; Zhu W
Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
Yang Y; Sun X; Luo L; Peng R; Yang R; Cheng Z; Lv Y; Li H; Tang Q; Zhu W; Qiao D; Xu S
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300403. PubMed ID: 37840368
[TBL] [Abstract][Full Text] [Related]
4. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
5. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
6. 3-Arylamino-quinoxaline-2-carboxamides inhibit the PI3K/Akt/mTOR signaling pathways to activate P53 and induce apoptosis.
Chen NY; Lu K; Yuan JM; Li XJ; Gu ZY; Pan CX; Mo DL; Su GF
Bioorg Chem; 2021 Sep; 114():105101. PubMed ID: 34175723
[TBL] [Abstract][Full Text] [Related]
7. Benzo[b]furan derivatives induces apoptosis by targeting the PI3K/Akt/mTOR signaling pathway in human breast cancer cells.
Kamal A; Lakshma Nayak V; Nagesh N; Vishnuvardhan MV; Subba Reddy NV
Bioorg Chem; 2016 Jun; 66():124-31. PubMed ID: 27149364
[TBL] [Abstract][Full Text] [Related]
8. Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells.
Pan ST; Qin Y; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1601-26. PubMed ID: 25834400
[TBL] [Abstract][Full Text] [Related]
9. Ampelopsin induces MDA-MB-231 cell cycle arrest through cyclin B1-mediated PI3K/AKT/mTOR pathway
Meng M; Yang Q; Ouyang Z; Yang Q; Wu X; Huang Y; Su Y; Chen S; Chen W
Acta Pharm; 2023 Mar; 73(1):75-90. PubMed ID: 36692465
[TBL] [Abstract][Full Text] [Related]
10. Deoxyshikonin isolated from
Zhu Y; Zhong Y; Long X; Zhu Z; Zhou Y; Ye H; Zeng X; Zheng X
Pharm Biol; 2019 Dec; 57(1):412-423. PubMed ID: 31230505
[No Abstract] [Full Text] [Related]
11. A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.
Wang S; Zhang Y; Ren T; Wu Q; Lu H; Qin X; Liu Y; Ding H; Zhao Q
Cell Death Dis; 2020 Jun; 11(6):491. PubMed ID: 32606352
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
13. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
Li KW; Wang SH; Wei X; Hou YZ; Li ZH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
[TBL] [Abstract][Full Text] [Related]
15. Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Aggarwal S; John S; Sapra L; Sharma SC; Das SN
Cancer Chemother Pharmacol; 2019 Mar; 83(3):451-461. PubMed ID: 30519710
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway.
Ma Y; Yang X; Han H; Wen Z; Yang M; Zhang Y; Fu J; Wang X; Yin T; Lu G; Qi J; Lin H; Wang X; Yang Y
Bioorg Chem; 2021 Jun; 111():104872. PubMed ID: 33838560
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking, anti-proliferative activity and induction of apoptosis in human liver cancer cells treated with androstane derivatives: Implication of PI3K/AKT/mTOR pathway.
Kattan SW; Nafie MS; Elmgeed GA; Alelwani W; Badar M; Tantawy MA
J Steroid Biochem Mol Biol; 2020 Apr; 198():105604. PubMed ID: 31982513
[TBL] [Abstract][Full Text] [Related]
18. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.
Mardanshahi A; Gharibkandi NA; Vaseghi S; Abedi SM; Molavipordanjani S
Mol Biol Rep; 2021 Aug; 48(8):1-14. PubMed ID: 34357550
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of a Fluorine-18 (
Altine B; Gai Y; Han N; Jiang Y; Ji H; Fang H; Niyonkuru A; Bakari KH; Rajab Arnous MM; Liu Q; Zhang Y; Lan X
Mol Pharm; 2019 Nov; 16(11):4563-4571. PubMed ID: 31553879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
